Table 3 Description of patient cohort included in survival analysis (n = 63 patients)

Patient sample (n)

34

29

Age at 1^st diagnosis (median; range)

56 (22–76)

62 (33–78)

Sex (male: female; n)

20:14

16:13

KPS (median; range)

8 (4–10)

6 (3–9)

MGMT promoter hypermethylation (%)

64,7

55,2

Overall survival (median: days (months))

480 (15)

429 (14)

Progression-free survival (median: days (months))

186 (6)

180 (5)

Survival after relapse (median: days (months))

266 (9)

187 (6)

Complete resection at 1^st surgery (%)

32,4

31

Radiotherapy at 1^st diagnosis (%)

100

100

TMZ at 1^st diagnosis (%)

14,7

17,2

Therapies other than BCNU at recurrence (re-resection, re-irradiation, TMZ, CCNU, thalidomide)

38,2

24,1

BCNU cycles (% of patients)

N/A

 - ≤6

88,2

 - 7–10

5,9

 - not determinable

5,9